blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4014048

EP4014048 - NOVEL DIAGNOSTIC MARKER FOR CREUTZFELDT-JAKOB DISEASE AND ALZHEIMER'S DISEASE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.11.2025
Database last updated on 28.02.2026
FormerThe patent has been granted
Status updated on  06.12.2024
FormerGrant of patent is intended
Status updated on  07.08.2024
FormerExamination is in progress
Status updated on  24.11.2023
FormerRequest for examination was made
Status updated on  20.05.2022
FormerThe international publication has been made
Status updated on  19.02.2021
Formerunknown
Status updated on  14.08.2020
Most recent event   Tooltip14.11.2025No opposition filed within time limitpublished on 17.12.2025  [2025/51]
Applicant(s)For all designated states
Otto, Markus
Hasslerstrasse 52
89077 Ulm / DE
For all designated states
Öckl, Patrick Christian
Am Espach 9
88447 Warthausen / DE
For all designated states
Halbgebauer, Steffen
Kasernstraße 22
89231 Neu-Ulm / DE
[2025/02]
Former [2022/25]For all designated states
Otto, Markus
Hasslerstrasse 52
89077 Ulm / DE
For all designated states
Öckl, Patrick Christian
Am Espach 9
88447 Warthausen / DE
For all designated states
Halbgebauer, Steffen
Kasernstraße 22
89231 Neu-Ulm / DE
Inventor(s)01 / see applicant
...
 [2022/25]
Representative(s)Klöckner, Christoph
df-mp Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
[N/P]
Former [2022/25]Klöckner, Christoph
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
Application number, filing date20751577.612.08.2020
[2022/25]
WO2020EP72559
Priority number, dateEP2019019121312.08.2019         Original published format: EP 19191213
[2022/25]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021028452
Date:18.02.2021
Language:EN
[2021/07]
Type: A1 Application with search report 
No.:EP4014048
Date:22.06.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 18.02.2021 takes the place of the publication of the European patent application.
[2022/25]
Type: B1 Patent specification 
No.:EP4014048
Date:08.01.2025
Language:EN
[2025/02]
Search report(s)International search report - published on:EP18.02.2021
ClassificationIPC:G01N33/68
[2022/25]
CPC:
G01N33/6896 (EP,US); G01N33/6848 (US); G01N2800/2814 (EP);
G01N2800/2821 (US); G01N2800/2828 (US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/25]  
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:NEUARTIGER DIAGNOSTISCHER MARKER FÜR DIE CREUTZFELDT-JAKOB-KRANKHEIT UND MORBUS ALZHEIMER[2022/25]
English:NOVEL DIAGNOSTIC MARKER FOR CREUTZFELDT-JAKOB DISEASE AND ALZHEIMER'S DISEASE[2022/25]
French:NOUVEAU MARQUEUR DE DIAGNOSTIC DE LA MALADIE DE CREUTZFELDT-JAKOB ET DE LA MALADIE D'ALZHEIMER[2022/25]
Entry into regional phase08.03.2022National basic fee paid 
08.03.2022Designation fee(s) paid 
08.03.2022Examination fee paid 
Examination procedure08.03.2022Examination requested  [2022/25]
08.03.2022Date on which the examining division has become responsible
06.10.2022Amendment by applicant (claims and/or description)
23.11.2023Despatch of a communication from the examining division (Time limit: M04)
22.03.2024Reply to a communication from the examining division
10.05.2024Despatch of a communication from the examining division (Time limit: M04)
27.06.2024Reply to a communication from the examining division
08.08.2024Communication of intention to grant the patent
04.12.2024Fee for grant paid
04.12.2024Fee for publishing/printing paid
04.12.2024Receipt of the translation of the claim(s)
Opposition(s)09.10.2025No opposition filed within time limit [2025/51]
Fees paidRenewal fee
08.03.2022Renewal fee patent year 03
21.08.2023Renewal fee patent year 04
26.08.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCZ08.01.2025
HR08.01.2025
PL08.01.2025
SK08.01.2025
SM08.01.2025
NO08.04.2025
RS08.04.2025
GR09.04.2025
IS08.05.2025
[2025/49]
Former [2025/48]CZ08.01.2025
HR08.01.2025
PL08.01.2025
SM08.01.2025
NO08.04.2025
RS08.04.2025
GR09.04.2025
IS08.05.2025
Former [2025/46]HR08.01.2025
PL08.01.2025
SM08.01.2025
NO08.04.2025
RS08.04.2025
GR09.04.2025
IS08.05.2025
Former [2025/35]HR08.01.2025
PL08.01.2025
NO08.04.2025
RS08.04.2025
GR09.04.2025
IS08.05.2025
Former [2025/34]HR08.01.2025
PL08.01.2025
NO08.04.2025
RS08.04.2025
IS08.05.2025
Former [2025/33]PL08.01.2025
RS08.04.2025
Cited inInternational search[XY] WO2018005791  (IMMUNARRAY USA INC et al.)
 [Y] WO2019099732  (BRAINBOX SOLUTIONS INC et al.)
 [XI] US2005176078  (ALLSOP DAVID et al.)
 [XI]   PATRICK OECKL ET AL: "Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies", MOLECULAR & CELLULAR PROTEOMICS, vol. 15, no. 10, 1 October 2016 (2016-10-01), US, pages 3126 - 3138, XP055659357, ISSN: 1535-9476, DOI: 10.1074/mcp.M116.059915

DOI:   http://dx.doi.org/10.1074/mcp.M116.059915
 [X]   K. BEYER ET AL: "The decrease of beta-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies", BRAIN, vol. 133, no. 12, 19 October 2010 (2010-10-19), pages 3724 - 3733, XP055222665, ISSN: 0006-8950, DOI: 10.1093/brain/awq275

DOI:   http://dx.doi.org/10.1093/brain/awq275
Examination  GELON PAULINE A. ET AL: "Synaptic dysfunction in ALS and FTD: anatomical and molecular changes provide insights into mechanisms of disease", FRONTIERS IN MOLECULAR NEUROSCIENCE, vol. 15, 3 October 2022 (2022-10-03), XP093102428, Retrieved from the Internet DOI: 10.3389/fnmol.2022.1000183 [P]

DOI:   http://dx.doi.org/10.3389/fnmol.2022.1000183
   OECKL PATRICK ET AL: "Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease", JOURNAL OF PROTEOME RESEARCH, vol. 19, no. 3, 26 February 2020 (2020-02-26), pages 1310 - 1318, XP093102540, ISSN: 1535-3893, DOI: 10.1021/acs.jproteome.9b00824 [P]

DOI:   http://dx.doi.org/10.1021/acs.jproteome.9b00824
   LORENZO BARBA: "Serum [beta]-synuclein, neurofilament light chain and glial fibrillary acidic protein as prognostic biomarkers in moderate-to-severe acute ischemic stroke", SCIENTIFIC REPORTS, vol. 13, no. 1, 28 November 2023 (2023-11-28), US, pages 20941, XP093159461, ISSN: 2045-2322, Retrieved from the Internet DOI: 10.1038/s41598-023-47765-7 [T]

DOI:   http://dx.doi.org/10.1038/s41598-023-47765-7
   REBECCA HALBGEBAUER: "Neurochemical Monitoring of Traumatic Brain Injury by the Combined Analysis of Plasma Beta-Synuclein, NfL, and GFAP in Polytraumatized Patients", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 23, no. 17, 25 August 2022 (2022-08-25), Basel, CH, pages 9639, XP093159463, ISSN: 1422-0067, Retrieved from the Internet DOI: 10.3390/ijms23179639 [T]

DOI:   http://dx.doi.org/10.3390/ijms23179639
   SAMIR ABU-RUMEILEH: "Plasma beta-synuclein, GFAP, and neurofilaments in patients with malignant gliomas undergoing surgical and adjuvant therapy", ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, vol. 10, no. 10, 23 August 2023 (2023-08-23), GB, pages 1924 - 1930, XP093159458, ISSN: 2328-9503, Retrieved from the Internet DOI: 10.1002/acn3.51878 [T]
by applicant  OECKL, P. ET AL., MOL. CELL. PROTEOMICS., vol. 15, 2016, pages 3126 - 3138
   MCKHANN, GM ET AL., ALZHEIMER'S DEMENT., vol. 7, 2011, pages 263 - 269
   RASCOVSKY, K. ET AL., BRAIN, vol. 134, 2011, pages 2456 - 77
   LUDOLPH, A. ET AL., AMYOTROPH. LATERAL SCLER. FRONTOTEMPORAL DEGENER., vol. 16, 2015, pages 291 - 2
   O'BRYANT, SE ET AL., ARCH. NEUROL., vol. 67, 2010, pages 746 - 9
   MACLEAN, B. ET AL., BIOINFORMATICS, vol. 26, 2010, pages 966 - 8
   DUBOIS B. ET AL., THE LANCET NEUROLOGY, vol. 13, 2014, pages 614 - 629
   BROOKS BR ET AL.: "Amyotrophic lateral sclerosis and other motor neuron disorders: official publication of the World Federation of Neurology", RESEARCH GROUP ON MOTOR NEURON DISEASES, vol. 1, 2000, pages 293 - 299
   HUGHES AJ ET AL., JOURNAL OF NEUROLOGY, NEUROSURGERY, AND PSYCHIATRY, vol. 55, 1992, pages 181 - 184
   HUGHES CP ET AL., THE BRITISH JOURNAL OF PSYCHIATRY: THE JOURNAL OF MENTAL SCIENCE, vol. 140, 1982, pages 566 - 572
   O'BRYANT, SE ET AL., ARCHIVES OF NEUROLOGY, vol. 65, 2008, pages 1091 - 1095
   LITVAN I ET AL.: "Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines", MOVEMENT DISORDERS: OFFICIAL JOURNAL OF THE MOVEMENT DISORDER SOCIETY, vol. 27, 2012, pages 349 - 356
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.